CervoMed Inc
CRVO5.310USD
+0.710+15.43%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
49.13M시가총액
손실P/E TTM
자세한 내용은 CervoMed Inc 회사
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
CervoMed Inc 정보
종목 코드 CRVO
회사 이름CervoMed Inc
상장일Nov 09, 2016
CEOAlam (John J)
직원 수15
유형Ordinary Share
회계 연도 종료Nov 09
주소20 Park Plaza, Suite 424
도시BOSTON
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호02116
전화16177444400
웹사이트https://cervomed.com/
종목 코드 CRVO
상장일Nov 09, 2016
CEOAlam (John J)
CervoMed Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Joshua S. Boger, Ph.D.
Dr. Joshua S. Boger, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.06M
--
Mr. John J. Alam, M.D.
Mr. John J. Alam, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
753.29K
+22500.00%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Independent Director
Independent Director
16.44K
--
Ms. Kelly Blackburn
Ms. Kelly Blackburn
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
13.67K
--
Ms. Jane H. Hollingsworth, M.D.
Ms. Jane H. Hollingsworth, M.D.
Independent Director
Independent Director
899.00
--
Dr. Robert J. Cobuzzi, Jr.
Dr. Robert J. Cobuzzi, Jr.
Director
Director
--
--
Mr. William R. Elder
Mr. William R. Elder
Chief Financial Officer, General Counsel, Corporate Secretary
Chief Financial Officer, General Counsel, Corporate Secretary
--
--
Dr. Sylvie L. Gregoire, Pharm.D.
Dr. Sylvie L. Gregoire, Pharm.D.
Director
Director
--
--
Dr. Marwan Noel Sabbagh, M.D.
Dr. Marwan Noel Sabbagh, M.D.
Independent Director
Independent Director
--
--
Mr. Frank E. Zavrl
Mr. Frank E. Zavrl
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Joshua S. Boger, Ph.D.
Dr. Joshua S. Boger, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.06M
--
Mr. John J. Alam, M.D.
Mr. John J. Alam, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
753.29K
+22500.00%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Independent Director
Independent Director
16.44K
--
Ms. Kelly Blackburn
Ms. Kelly Blackburn
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
13.67K
--
Ms. Jane H. Hollingsworth, M.D.
Ms. Jane H. Hollingsworth, M.D.
Independent Director
Independent Director
899.00
--
Dr. Robert J. Cobuzzi, Jr.
Dr. Robert J. Cobuzzi, Jr.
Director
Director
--
--
수익 분석
기업이 아직 관련 데이터를 공개하지 않았습니다.
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: 5 hours ago
마지막 업데이트: 5 hours ago
주주
주주 유형
주주
주주
비율
Boger (Joshua S)
11.43%
AWM Investment Company, Inc.
9.33%
Gregoire (Sylvie L.)
8.14%
Alam (John J)
8.14%
Morgan Stanley & Co. LLC
4.43%
기타
58.53%
주주
주주
비율
Boger (Joshua S)
11.43%
AWM Investment Company, Inc.
9.33%
Gregoire (Sylvie L.)
8.14%
Alam (John J)
8.14%
Morgan Stanley & Co. LLC
4.43%
기타
58.53%
주주 유형
주주
비율
Individual Investor
32.17%
Investment Advisor/Hedge Fund
11.31%
Investment Advisor
6.63%
Research Firm
4.45%
Hedge Fund
1.59%
기타
43.85%
기관 주식 보유
마지막 업데이트: Mon, Dec 8
마지막 업데이트: Mon, Dec 8
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
123
2.18M
45.61%
--
2025Q3
124
2.18M
46.47%
-3.07K
2025Q2
112
2.18M
47.13%
-111.10K
2025Q1
106
2.29M
39.48%
-1.15M
2024Q4
98
1.50M
41.86%
-2.03M
2024Q3
82
3.52M
43.30%
+50.30K
2024Q2
68
3.46M
36.20%
+585.47K
2024Q1
43
2.52M
7.33%
+2.06M
2023Q4
40
327.50K
7.25%
-36.20K
2023Q3
40
363.70K
2.81%
+241.80K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Boger (Joshua S)
1.06M
11.43%
--
--
Apr 24, 2025
AWM Investment Company, Inc.
863.20K
9.33%
--
--
Sep 30, 2025
Gregoire (Sylvie L.)
753.29K
8.14%
+22.50K
+3.08%
Nov 17, 2025
Alam (John J)
753.29K
8.14%
+22.50K
+3.08%
Nov 17, 2025
Morgan Stanley & Co. LLC
410.15K
4.43%
+38.92K
+10.48%
Sep 30, 2025
The Vanguard Group, Inc.
343.46K
3.71%
+3.44K
+1.01%
Sep 30, 2025
Zavrl (Frank E.)
353.01K
3.82%
--
--
Apr 24, 2025
Millennium Management LLC
71.51K
0.77%
-4.57K
-6.01%
Sep 30, 2025
Geode Capital Management, L.L.C.
64.47K
0.7%
+10.21K
+18.82%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
47.76K
0.52%
-49.82K
-51.05%
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Health Innovation Active ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
iShares Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
비율0.01%
iShares Russell 2000 Growth ETF
비율0%
Global X Russell 2000 ETF
비율0%
Proshares Ultra Russell 2000
비율0%
ProShares UltraPro Russell2000
비율0%
iShares Health Innovation Active ETF
비율0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
비율0%
iShares Russell 2000 ETF
비율0%
ProShares Hedge Replication ETF
비율0%
Avantis US Small Cap Equity ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
Aug 16, 2023
Merger
1.5→1
Aug 16, 2023
Merger
1.5→1
Aug 16, 2023
Merger
1.5→1
Aug 16, 2023
Merger
1.5→1
Apr 18, 2022
Merger
50→1
Apr 18, 2022
Merger
50→1
날짜
배당락일
유형
비율
Aug 16, 2023
Merger
1.5→1
Aug 16, 2023
Merger
1.5→1
Aug 16, 2023
Merger
1.5→1
Aug 16, 2023
Merger
1.5→1
Apr 18, 2022
Merger
50→1
Apr 18, 2022
Merger
50→1
Apr 18, 2022
Merger
50→1
Apr 18, 2022
Merger
50→1
